Interleukin-17A Antagonist [EPC]

37285 reported adverse events

Drugs of this class: IXEKIZUMAB SECUKINUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-17A Antagonist [EPC] class:

# Side effect Count
0 INJECTION SITE PAIN 3931
1 PSORIASIS 3296
2 DRUG INEFFECTIVE 3287
3 INJECTION SITE ERYTHEMA 2214
4 INJECTION SITE REACTION 1798
5 INJECTION SITE SWELLING 1659
6 INCORRECT DOSE ADMINISTERED 1199
7 PRODUCT DOSE OMISSION ISSUE 962
8 PAIN 950
9 COVID-19 923
See all common reactions for Interleukin-17A Antagonist [EPC]

Drugs of the Interleukin-17A Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 INJECTION SITE URTICARIA 676 0.0275
1 INJECTION SITE REACTION 1798 0.0261
2 PSORIASIS 3296 0.0252
3 INJECTION SITE WARMTH 501 0.0243
4 INJECTION SITE SWELLING 1659 0.0216
5 PSORIATIC ARTHROPATHY 821 0.0202
6 INJECTION SITE RASH 549 0.0179
7 INJECTION SITE ERYTHEMA 2214 0.0178
8 INJECTION SITE MASS 622 0.0168
9 INFLAMMATORY BOWEL DISEASE 145 0.0148
See all enriched reactions for Interleukin-17A Antagonist [EPC]